CD14 and rheumatoid arthritis: Thus, the number of monocytes, and of their CD14+highCD16-, CD14+highCD16+ and CD14+lowCD16+ subsets, in peripheral blood would appear to be a practical biomarker for predicting the response to anti-TNFα in patients with RA.